Financial PerformanceAdjusted operating margin was slightly below expectations, reflecting ongoing supply chain pressures and cost-saving program delays.
Interest And DevelopmentHigh interest rates may limit Medtronic's research and development capabilities, potentially delaying new product launches that could drive share price growth.
Market CompetitionThe growing popularity of GLP-1 drugs could significantly impact Medtronic's insulin pump sales, with a risk of losing 50% of its market share.